Newsfeeds - Spark Newswire

1 minute read

Turning Point Q3 EPS $(1.34) Misses $(1.27) Estimate

Today, 8:19 PM

Turning Point (NASDAQ:TPTX) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.27) by 5.51 percent. This is a 219.05 percent decrease over losses of $(0.42) per share from

TPTX

6 minute read

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

By Shanthi Rexaline

Today, 8:19 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACHV

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 8:19 PM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

3 minute read

Turning Point Therapeutics Early Saturday Highlighted Presentation Of Early Clinical Data For Repotrectinib From Care Study In Pediatric, Young Adult Patients At International Society of Paediatric Oncology Meeting

By Benzinga Newsdesk

Today, 8:19 PM

Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses in 3 of 4

TPTX

4 minute read

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts

By Shanthi Rexaline

Today, 8:19 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

CBIO

2 minute read

FDA
News

Turning Point Therapeutics, EQRx Announce Clinical Collaboration To Evaluate Elzovantinib In Combination With Aumolertinib In Patients With EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer

By Benzinga Newsdesk

Today, 8:19 PM

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to

TPTX

1 minute read

HC Wainwright & Co. Maintains Buy on Turning Point, Lowers Price Target to $162

By Benzinga Newsdesk

Today, 8:19 PM

HC Wainwright & Co. analyst Robert Burns maintains Turning Point (NASDAQ:TPTX) with a Buy and lowers the price target from $178 to $162.

TPTX

1 minute read

Turning Point Therapeutics To Present Early Clinical Data For Repotrectinib From CARE Study Oct. 23

By Benzinga Newsdesk

Today, 8:19 PM

Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical data for

TPTX